Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 652-654

  Roche, Bruno ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; NORFLOXACIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; BACTERIAL PERITONITIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG FATALITY; DRUG WITHDRAWAL; EDITORIAL; HEPATITIS C; HUMAN; INFECTION; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT INFECTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 61749086694     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.008     Document Type: Editorial

References (12)

1. Terrault N.A., and Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 12 (2006) 1192-1204
2. Hadzyiannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon alpha-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
3. Crippin J.S., McCashland T., Terrault N., Sheiner P., and Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8 (2002) 350-355
4. Thomas R.M., Brems J.J., Guzman-Hartman G., Yong S., Cavaliere P., and Van Thiel D.H. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 9 (2003) 905-915
5. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39 (2003) 389-396
6. Everson G.T., Trotter J., Forman L., Kugelmas M., Halprin A., Fey B., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 (2005) 255-262
7. Charlton M., Seaberg E., Wiesner R., Everhart J., Zetterman R., Lake J., et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28 (1998) 823-830
8. Iacobellis A., Siciliano M., Perri F., Annicchiarico B.E., Leandro G., Caruso N., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 46 (2007) 206-212
9. Di Marco V., Almasio P.L., Ferraro D., Calvaruso V., Alaimo G., Peralta S., et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 47 (2007) 484-491
10. Tekin F., Gunsar F., Karasu Z., Akarca U., and Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 27 (2008) 1081-1085
11. Carrión J.A., Martínez-Bauer E., Crespo G., Ramírez S., Pérez-del-Pulgar S., García-Valdecasas J.C., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 50 (2009) 719-728
12. Marcellin P., Samuel D., Areias J., Loriot M.A., Arulnaden J.L., Gigou M., et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 19 (1994) 6-12